DDInter1323 DDInter1658
Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may also occur. Acromegaly is a life-threatening disease requiring life-long management. Octreotide is a long-acting drug with pharmacologic activities that mimic those of the natural hormone, somatostatin, which inhibits the secretion of growth hormone. Additionally, it is used for the treatment of acromegaly and symptoms arising from various tumors, including carcinoid tumors and vasoactive intestinal tumors (VIPomas). In the past, octreotide has been administered solely by injection. On June 26, 2020, the first approved delayed-release oral somatostatin analog, Mycapssa, received FDA approval for the long term maintenance
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Octreotide {u} (Compound) resembles {v} (Compound) Polymyxin B
Octreotide {u} (Compound) resembles {v} (Compound) Bacitracin
Octreotide {u} (Compound) treats {v} (Disease) thymus cancer
Octreotide {u} (Compound) binds {v} (Gene) SSTR2
Octreotide {u} (Compound) palliates {v} (Disease) type 1 diabetes mellitus
Octreotide {u} (Compound) is included by {v} (Pharmacologic Class) Somatostatin Receptor Agonists
Octreotide {u} (Compound) causes {v} (Side Effect) Arthropathy
Octreotide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Octreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lefamulin
Octreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin human
Octreotide (Compound) resembles Polymyxin B (Compound)
Octreotide (Compound) resembles Bacitracin (Compound)
Octreotide (Compound) treats thymus cancer (Disease)
Octreotide (Compound) binds SSTR2 (Gene)
Octreotide (Compound) palliates type 1 diabetes mellitus (Disease)
Octreotide (Compound) is included by Somatostatin Receptor Agonists (Pharmacologic Class)
Octreotide (Compound) causes Arthropathy (Side Effect)
Octreotide may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Insulin human